← Back to Clinical Trials
Recruiting NCT06198010

NCT06198010 A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06198010
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Hematopoietic and Lymphoid System Neoplasm
Study Type INTERVENTIONAL
Enrollment 660 participants
Start Date 2024-02-07
Primary Completion 2027-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Best PracticeEducational InterventionQuestionnaire Administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 660 participants in total. It began in 2024-02-07 with a primary completion date of 2027-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial tests a collaborative pain management intervention (ASCENT) for improving cancer pain in cancer survivors. Cancer pain is prevalent, under-treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain interventions and care models show promise for cancer pain in controlled settings. All cancer survivors stand to benefit from electronic health record innovations, as they can experience profound pain outcomes, including marked under- and over-prescribing of opioids. Digitally facilitated solutions are especially helpful and can be customized to address patient needs. The ASCENT intervention provides patients with an educational guide that describes techniques for addressing cancer pain, and uses community health workers and pain care managers to coach patients through a personalized pain management plan. This study may help researchers learn how pain management strategies can improve cancer pain and lower risk of opioid exposure and dependency in cancer survivors.

Eligibility Criteria

Inclusion Criteria: * A qualifying liquid or solid cancer diagnosis with visits at a participating Mayo site in the past 15 years * Including malignant hematology * Lymphoma * Myeloma * Chronic leukemias * Age \>= 18 * Numeric Rating Scale (NRS) pain score of \>= 5/10 * Pain that developed or worsened following cancer diagnosis * Fit the description of either rural or Hispanic or both Exclusion Criteria: * Patient Health Questionnaire - 8 (PHQ8) score of \>= 13 * Hospice enrollment * Skilled nursing facility, inpatient rehabilitation facility, or long-term care placement * Encounters with Palliative Care or the Pain Clinic in the past two months or upcoming two months * Any mention of hospice referral in medical oncology encounter notes (assess through textual search of the Mayo Data Explorer) * Affirmative response to, "Are you usually confined to a bed or chair more than a third of your waking hours because of your health?" * Currently homeless * Do not feel safe in their home * New or worsening chest pain, chest tightness, or chest pressure * Back pain that is associated with a new or worsening weakness, control of bowels/bladder, or difficulty walking * Lightheadedness, inability to keep down food or fluids, or vomiting blood or dark coffee-grounds-like material * New or worsening headaches that are associated with vision changes, nausea, balance issues, or problems with speech * Screens positive for use of non-cannabis drug use a a frequency of monthly or greater * Inability to engage with the intervention due to medical or psychological response

Contact & Investigator

Central Contact

Clinical Trials Referral Office

✉ mayocliniccancerstudies@mayo.edu

📞 507-293-1043

Principal Investigator

Andrea L. Cheville, M.D.

PRINCIPAL INVESTIGATOR

Mayo Clinic in Rochester

Frequently Asked Questions

Who can join the NCT06198010 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06198010 currently recruiting?

Yes, NCT06198010 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.

Where is the NCT06198010 trial being conducted?

This trial is being conducted at Scottsdale, United States, Jacksonville, United States, Rochester, United States.

Who is sponsoring the NCT06198010 clinical trial?

NCT06198010 is sponsored by Mayo Clinic. The principal investigator is Andrea L. Cheville, M.D. at Mayo Clinic in Rochester. The trial plans to enroll 660 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology